Skip to content

Latest news

Attgeno - develops new drug candidates for treatment of acute pulmonary hypertension using technology based on ground-breaking nitric oxide research

Attgeno is a Swedish, clinical stage, pharmaceutical company developing new, innovative and efficient nitric oxide-donating drugs. Our technology allows us to tailor drugs to release nitric oxide to specific organs in the body. Our primary goal bring our first drug candidate, Supernitro to the patients as a treatment for acute pulmonary hypertension, high pressure in the lung blood circulation, a life-threatening condition that occurs in a large number of different critical illnesses.

Fogdevreten 2A
171 65 Solna
Visit our other newsrooms